Market advancements are driven by rising incidences of neuroendocrine tumors, improved diagnostics, and targeted therapies. Key players like Novartis AG and Pfizer Inc. are investing in innovative ...

Dublin, April 21, 2025 (GLOBE NEWSWIRE) -- The "Gastric Neuroendocrine Tumors Market" report has been added to ResearchAndMarkets.com's offering. The gastric neuroendocrine tumor (gNET ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

Exercise is a powerful modulator of gut health in patients with gastrointestinal (GI) conditions, as moderate activity can ...

Sunshine Biopharma (SBFM) announced that its wholly owned Canadian subsidiary, Nora Pharma, has launched Everolimus in the Canadian generic ...

President Trump weighed in on the cost of eggs around the country, claiming Friday at the White House that the prices are ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

Explore GISTs, rare GI tumors. Discover key details on genetic causes, diagnostic methods, and cutting-edge treatment ...